Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pulmonx (LUNG) Cash from Operations (2019 - 2025)

Historic Cash from Operations for Pulmonx (LUNG) over the last 7 years, with Q3 2025 value amounting to -$8.2 million.

  • Pulmonx's Cash from Operations fell 1336.2% to -$8.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$32.0 million, marking a year-over-year increase of 357.35%. This contributed to the annual value of -$31.5 million for FY2024, which is 1614.73% up from last year.
  • Pulmonx's Cash from Operations amounted to -$8.2 million in Q3 2025, which was down 1336.2% from -$3.9 million recorded in Q2 2025.
  • Pulmonx's Cash from Operations' 5-year high stood at -$3.9 million during Q2 2025, with a 5-year trough of -$15.0 million in Q1 2022.
  • Its 5-year average for Cash from Operations is -$9.5 million, with a median of -$9.6 million in 2022.
  • As far as peak fluctuations go, Pulmonx's Cash from Operations crashed by 6508.51% in 2021, and later skyrocketed by 3262.07% in 2025.
  • Over the past 5 years, Pulmonx's Cash from Operations (Quarter) stood at -$10.7 million in 2021, then rose by 8.41% to -$9.8 million in 2022, then increased by 14.18% to -$8.4 million in 2023, then grew by 19.98% to -$6.7 million in 2024, then fell by 21.4% to -$8.2 million in 2025.
  • Its Cash from Operations stands at -$8.2 million for Q3 2025, versus -$3.9 million for Q2 2025 and -$13.2 million for Q1 2025.